Evaluation of the effectiveness of Raphanus sativus in melasma
Phase 3
- Conditions
- Melasma.L81.0
- Registration Number
- IRCT20220223054106N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
Clinical diagnosis of melasma by a dermatologist (at the Center for Dermatology and Leprosy Research)
Female gender
Age of over 18 years
Bilateral facial melasma
Exclusion Criteria
Pregnancy and breastfeeding
Use of any topical treatment for melasma during 2 months before the start of the study
Taking oral contraceptives and hormonal drugs for 4 weeks before the study
Use of drugs that increase sensitivity to sunlight; Such as doxycycline, minocycline, tetracycline, ciprofloxacin, hydrochlorothiazide and sulfonamides
The presence of scars, tattoos, excessive hair, or any other condition that makes the test site less likely to be evaluated
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method